NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2031220487

Registered date:04/12/2022

Special Use-results Survery of Rituxan Intravenous Injection - Relapse Prevention of Neuromyelitis Optica Spectrum Disorder (including Neuromyelitis Optica) -

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedneuromyelitis optica spectrum disorder (including neuromyelitis optica)
Date of first enrollment04/12/2022
Target sample size200
Countries of recruitment
Study typeObservational
Intervention(s)

Outcome(s)

Primary OutcomeIncidence of adverse drug reactions and severe adverse events (including grade 3/4 laboratory abnormalities)
Secondary Outcome

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderBoth
Include criteriaPatients who have received Rituxan intravenous injection for relapse prevention of neuromyelitis optica spectrum disorder (including neuromyelitis optica)
Exclude criterianone

Related Information

Contact

Public contact
Name Junko Sakamoto
Address 6-15, Otsuka 5-chome, Bunkyo-ku, Tokyo Tokyo Japan 112-8650
Telephone +81-339461136
E-mail Junko_Sakamoto@mail.zenyaku.co.jp
Affiliation Zenyaku Kogyo, Co., LTD.
Scientific contact
Name Takashi Ando
Address 6-15, Otsuka 5-chome, Bunkyo-ku, Tokyo Tokyo Japan 112-8650
Telephone +81-339461136
E-mail Takashi_Ando@mail.zenyaku.co.jp
Affiliation Zenyaku Kogyo, Co., LTD.